Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis
OBJECTIVES: To ascertain the occurrence of serious adverse effects associated with therapy for MDR-TB in northern Lima, Peru, where therapy was individualized according to drug-susceptibility testing of patients’ infecting strains and delivered through a community-based program.
DESIGN: A retrospective record review of 60 patients who had received individualized therapy for MDR-TB between September 1996 and October 1998.
RESULTS: Although adverse effects were common, they occurred less frequently than previously reported in the literature and were rarely life-threatening. Effects occurring most frequently in this population included: mild gastritis (100%), dermatological effects (43.3%), peripheral neuropathy (16.7%), depression (18.3%), and anxiety (11.7%). These effects never resulted in the discontinuation of anti-tuberculosis therapy, and only occasionally resulted in the suspension of an agent (11.7%).
CONCLUSION: In young patients with little comorbid disease, multidrug, long-course regimens rarely caused life-threatening adverse effects. Common side effects may be managed successfully on an out-patient basis through a community-based treatment program in conjunction with MDR-TB experts, even in resource-poor settings. The very low rate of default in this cohort offers hope that strategies to manage the adverse effects may reduce the incidence of abandonment of therapy and increase rates of cure.
Keywords: adverse effects; antimicrobial resistance; tuberculosis
Document Type: Regular Paper
Affiliations: 1: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Brigham and WomenÕs Hospital, Boston, Massachusetts, USA 2: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Department of Population and International Health, Harvard School of Public Health, Boston, Massachusetts, USA 3: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA and Socios En Salud—Sucursal Peru/Partners In Health, Carabayllo, Peru 4: Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, Boston, Massachusetts, USA 5: Socios En Salud—Sucursal Peru/Partners In Health, Carabayllo, Peru 6: Servicio de Neurología, Instituto Nacional de Salud Mental ‘Honorio Delgado-Hideyo Noguchi’, Lima, Peru 7: National Tuberculosis Program, Lima, Peru and Hospital Sergio E. Bernales, Comas, Peru
Publication date: 01 July 2001
The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.
The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- International Journal of Tuberculosis and Lung Disease
- Public Health Action
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content